DePaul, M. A. et al. Intravenous multipotent adult progenitor cell treatment decreases inflammation leading to functional recovery following spinal cord injury. Sci. Rep. 5, 16795; doi: 10.1038/srep16795 (2015).
Marc A. DePaul1, Marc Palmer2, Bradley T. Lang1,2, Rochelle Cutrone2, Amanda P. Tran1,Kathryn M. Madalena1, Annelies Bogaerts3, Jason A. Hamilton2, Robert J. Deans2,Robert W. Mays2, Sarah A. Busch2 & Jerry Silver1
1Case Western Reserve Univ., Dept. of Neurosciences, 10900 Euclid Ave., SOM E654, Cleveland, OH, 44106, USA.2Athersys, Inc. Regenerative Medicine, Cleveland, OH, 44115, USAs. 3ReGenesys, Bioincubator Leuven, 3001,Leuven, Belgium.
Acknowledgements: The authors thank the Spinal Cord Injury Research Training Program at Ohio State University for surgical and behavioral training and guidance, and Jared Cregg, Yu-Shang Lee, JingQiang You, Warren Alilain, Sarah Zilka Starke, and Anthony Ting for their valuable input into the project. This work was supported by an Ohio Third Frontier Grant to the National Center for Regenerative Medicine, National Institute of Neurological Disorders and Stroke grant NS025713 (J.S.); the Case Western Reserve University Council to Advance Human Health; P. Jing, R. Senior and S. Poon; Unite to Fight Paralysis; The Brumagin Memorial Fund; Spinal Cord Injury Sucks; United Paralysis Foundation; and The Kaneko Family Fund.
This study builds on a decade-long collaboration between Athersys and Case Western Reserve University School of Medicine, led by Professor Jerry Silver, Ph.D., of the Department of Neurosciences. Dr. Silver stated, “Spinal cord injury continues to devastate the lives of many. Although a great deal of research needs to be undertaken in the field, we are pleased to see that MultiStem therapy is efficacious in promoting the recovery of locomotor and urinary functions in rodents. I am especially excited with this therapy as it circumvents the need for directed therapeutic delivery into the vulnerable, recently injured spinal cord. We look forward to working with Athersys and other leaders in the science community to fill this critical treatment gap.”
This study provides additional strong support for the use of MultiStem as a therapeutic for human acute spinal cord injury with the overall goals of improving quality of life, motor control, and reducing long-term patient care costs. According to the Christopher and Dana Reeve Foundation, the cost of spinal cord injury is estimated to be from $500,000 to more than $3 million per patient, depending on severity. Donna Sullivan, Project Director for Unite 2 Fight Paralysis, commented, “We are excited by these results in rodent models of spinal cord injury, which demonstrate that MultiStem therapy may have the potential to enhance patients’ lives by improving critical locomotor and bladder functions. Improvement in these functions will reduce the many life threatening secondary conditions, which are a result of the loss of these functions. Unite 2 Fight Paralysis looks forward to additional opportunities to partner with this team of scientists to bring this cell therapy to the bedside.”
The research was coordinated by Dr. Sarah Busch and other Athersys scientists in collaboration with Dr. Jerry Silver, graduate student Marc DePaul, and other scientists from Case Western Reserve University School of Medicine, with grant support from The Ohio Third Frontier.
Additional information about MAPC from Athersys can be found HERE.